These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 7106619)

  • 21. Disappearance of phenazone from plasma in patients with obstructive jaundice.
    Elfström J; Lindgren S
    Eur J Clin Pharmacol; 1974 Oct; 7(6):467-71. PubMed ID: 4439871
    [No Abstract]   [Full Text] [Related]  

  • 22. Etoposide kinetics in patients with obstructive jaundice.
    Hande KR; Wolff SN; Greco FA; Hainsworth JD; Reed G; Johnson DH
    J Clin Oncol; 1990 Jun; 8(6):1101-7. PubMed ID: 2348225
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The plasma half-life of antipyrine in chromic uraemic and normal subjects.
    Maddocks JL; Wake CJ; Harber MJ
    Br J Clin Pharmacol; 1975 Aug; 2(4):339-43. PubMed ID: 1233993
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of physical exercise on one-sample antipyrine clearance.
    Fabbri A; Bianchi G; Zoli M; Marchi E; Marchesini G
    Ital J Gastroenterol; 1991 Feb; 23(2):74-6. PubMed ID: 1747507
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effect of six beta-adrenolytics and labetalol on hepatic biotransformation studied by antipyrine test, in man.
    Adamska-Dyniewska H; Dziekański S; Pruszczyński J
    Int J Clin Pharmacol Ther Toxicol; 1986 Jun; 24(6):303-7. PubMed ID: 2874117
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of etiocholanolone-induced fever on plasma antipyrine half-lives and metabolic clearance.
    Elin RJ; Vesell ES; Wolff SM
    Clin Pharmacol Ther; 1975 Apr; 17(4):447-57. PubMed ID: 1122686
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Estimation of functional liver reserve in patients before cardiac surgery using antipyrine plasma clearance test.
    Takeda M; Furuse A; Kawauchi M; Kotsuka Y; Takamoto S
    J Cardiovasc Surg (Torino); 1999 Dec; 40(6):817-23. PubMed ID: 10776711
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetic parameters of antipyrine in dog after hepatectomy.
    Galtier M; Briand D; Pinguet F; Gomeni R; Fabre D; Bressolle F
    Biopharm Drug Dispos; 1995 Nov; 16(8):669-84. PubMed ID: 8573686
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Saliva and plasma clearance of antipyrine as reflectors of liver function.
    Luoma PV; Sotaniemi EA
    Eur J Drug Metab Pharmacokinet; 1981; 6(4):261-4. PubMed ID: 7333326
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genetic control of the phenobarbital-induced shortening of plasma antipyrine half-lives in man.
    Vesell ES; Page JG
    J Clin Invest; 1969 Dec; 48(12):2202-9. PubMed ID: 5389794
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of MEGX (monoethylglycinexylidide) and antipyrine tests in patients with liver cirrhosis.
    Wojcicki J; Kozlowski K; Drozdzik M; Wojcicki M
    Eur J Drug Metab Pharmacokinet; 2002; 27(4):243-7. PubMed ID: 12587953
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Plasma antipyrine half-life can be determined from urine data.
    Atiba JO; Taylor G; Pershe RA; Blaschke TF
    Br J Clin Pharmacol; 1987 Jun; 23(6):715-9. PubMed ID: 2440468
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Profile of hepatocyte growth factor in patients with obstructive jaundice.
    Hu RH; Lee PH; Yu SC; Ho MC
    Hepatogastroenterology; 2003; 50(54):1987-90. PubMed ID: 14696449
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impairment of hepatic drug metabolism in patients with acute viral hepatitis.
    Narang AP; Datta DV; Nath N; Mathur VS
    Eur J Drug Metab Pharmacokinet; 1982; 7(4):255-8. PubMed ID: 7166177
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Quantification of the drug-metabolizing enzyme system in liver diseases: a comparison between antipyrine saliva clearance and the aminopyrine breath test].
    von Mandach U; Jost G; Preisig R
    Schweiz Med Wochenschr; 1985 May; 115(19):651-8. PubMed ID: 3923620
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impairment of hepatic drug metabolism in alcoholics.
    Harman AW; Frewin DB; Priestly BG; Alexander CB
    Br J Clin Pharmacol; 1979 Jan; 7(1):45-8. PubMed ID: 760741
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Recovery patterns of liver function after complete and partial surgical biliary decompression.
    Watanapa P
    Am J Surg; 1996 Feb; 171(2):230-4. PubMed ID: 8619456
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparative investigation of antipyrine half-life and induction of cytochrome P-450 dependent monooxygenases in rats treated with phenylurea herbicides.
    Schoket B; Zilahy Z; Molnar J; Vincze I
    In Vivo; 1987; 1(3):185-7. PubMed ID: 2979785
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cholestasis and hepatic drug metabolism. Comparison of metabolic clearance rate of antipyrine in patients with intrahepatic or extrahepatic cholestasis.
    Miguet JP; Vuitton D; Deschamps JP; Allemand H; Joanne C; Bechtel P; Carayon P
    Dig Dis Sci; 1981 Aug; 26(8):718-22. PubMed ID: 7261836
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rapid normalization of antipyrine oxidation by heme in variegate porphyria.
    Mustajoki P; Himberg JJ; Tokola O; Tenhunen R
    Clin Pharmacol Ther; 1992 Mar; 51(3):320-4. PubMed ID: 1544288
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.